{"schema_version":"1.0","type":"article","title":"Avexitide Reduced the Composite Rate of Level 2/3 Hypoglycemia Events by 55%—and Repriced Amylyx Overnight","url":"https://drugnews.com.tw/articles/2026-08-30-amylyx-avexitide-pbh-phase3-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-30-amylyx-avexitide-pbh-phase3-en.md","lang":"en","date":"2026-08-30","publish_at":"2026-08-30T08:00:13+08:00","updated_at":"2026-08-30","category":"基本面系列","topic":"基本面系列","tags":["Amylyx","avexitide","GLP-1","post-bariatric hypoglycemia","PBH","LUCIDITY","Relyvrio","MBX Biosciences","biotech asset acquisition"],"summary":"Avexitide reduced the combined rate of Level 2 and Level 3 hypoglycemic events by 55% versus placebo in Amylyx's Phase 3 LUCIDITY trial, sending the shares up about 64% in one session. This analysis examines the GLP-1 mechanism in post-bariatric hypoglycemia, the evidence still missing from the topline release, Amylyx's $35.1 million asset acquisition, its $500.2 million financing and the regulatory and commercial gates ahead.","key_points":[],"facts":[],"sections":["01 | Why Can a Successful Bariatric Procedure Make a Meal Dangerous?","02 | Why Did a 78-Patient Phase 3 Trial Move the Market So Much?","03 | The More Dramatic Turnaround Belongs to Amylyx Itself","04 | Beyond the 64% Share-Price Move, Amylyx Immediately Raised Capital","05 | Three Gates Still Separate the Trial From a Launch","06 | Once-Weekly Imapextide Validated a Concept, but MBX Is Not Funding Phase 2b","07 | Investors Now Need to Model More Than Probability of Success","Conclusion | The Real Turnaround Will Not Be Measured by One Trading Day","Primary Sources"],"references":[{"title":"[Amylyx","source":"Positive topline results from Phase 3 LUCIDITY]","date":"","url":"https://investors.amylyx.com/news-releases/news-release-details/amylyx-pharmaceuticals-announces-positive-topline-results-0"},{"title":"[Amylyx","source":"Acquisition of the Phase 3-ready avexitide asset]","date":"","url":"https://investors.amylyx.com/news-releases/news-release-details/amylyx-pharmaceuticals-announces-acquisition-phase-3-ready-glp-1"},{"title":"[Amylyx","source":"Formal intention to remove RELYVRIO and corporate restructuring]","date":"","url":"https://investors.amylyx.com/news-releases/news-release-details/amylyx-pharmaceuticals-announces-formal-intention-remove"},{"title":"[Amylyx","source":"Historical stock-price lookup]","date":"","url":"https://investors.amylyx.com/stock-information/historical-price-lookup"},{"title":"[Amylyx","source":"Pricing of the upsized approximately $500.2 million offering]","date":"","url":"https://investors.amylyx.com/news-releases/news-release-details/amylyx-pharmaceuticals-announces-pricing-upsized-500-million"},{"title":"[MBX Biosciences","source":"Imapextide Phase 2 update]","date":"","url":"https://investors.mbxbio.com/news-releases/news-release-details/mbx-biosciences-provides-obesity-portfolio-update-including"},{"title":"Fact-check cutoff: August 30, 2026.","source":"","date":"","url":""},{"title":"> Disclaimer: This article is intended for biotechnology industry and investment education. It does not constitute medical, treatment or investment advice. Avexitide is not FDA approved, and the complete Phase 3 dataset has not yet been presented at a medical meeting.","source":"","date":"","url":""}],"images":[{"alt":"Amylyx moved from the withdrawal of Relyvrio to a positive Phase 3 result with a GLP-1 receptor antagonist","url":"https://drugnews.com.tw/assets/articles/amylyx-avexitide-pbh-phase3-en/figure-01.png"},{"alt":"In post-bariatric hypoglycemia, rapid nutrient delivery can drive excessive GLP-1 signaling, an insulin surge and a glucose crash; avexitide blocks the GLP-1 receptor","url":"https://drugnews.com.tw/assets/articles/amylyx-avexitide-pbh-phase3-en/figure-02.png"},{"alt":"LUCIDITY enrolled 78 adults for 16 weeks and reported a 55% reduction in the combined rate of Level 2 and Level 3 hypoglycemic events","url":"https://drugnews.com.tw/assets/articles/amylyx-avexitide-pbh-phase3-en/figure-03.png"},{"alt":"Amylyx withdrew Relyvrio, acquired avexitide for $35.1 million, reported a positive Phase 3 trial and then raised approximately $500.2 million","url":"https://drugnews.com.tw/assets/articles/amylyx-avexitide-pbh-phase3-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/amylyx-avexitide-pbh-phase3-en/cover-1400.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-30）。Avexitide Reduced the Composite Rate of Level 2/3 Hypoglycemia Events by 55%—and Repriced Amylyx Overnight。https://drugnews.com.tw/articles/2026-08-30-amylyx-avexitide-pbh-phase3-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-08-30-amylyx-avexitide-pbh-phase3.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}